June 24, 2026
As drug development becomes increasingly complex, sponsors are placing greater emphasis on preclinical partners that can do more than simply execute studies. They need research organizations capable of delivering clinically relevant models, sophisticated surgical procedures, and the scientific expertise necessary to generate data that translates effectively into human development programs.
That reality is driving growing interest in advanced surgical models, particularly in non-human primate (NHP) research. Few organizations have invested as heavily in this area as Envol Biomedical.
Today, Envol offers an expanding portfolio of specialized surgical capabilities that allow sponsors to evaluate therapies using clinically relevant administration routes, advanced disease models, and highly targeted delivery techniques. Combined with the organization’s continued investment in GLP leadership and scientific expertise, these capabilities are helping sponsors move from discovery to IND-enabling studies with greater confidence.
Surgical Expertise Designed Around Translational Relevance
One of the greatest challenges in preclinical development is creating models that accurately reflect how therapies will ultimately be delivered and evaluated in humans.
Envol’s surgical team is built around that challenge.
Led by experienced physician-scientists and supported by a growing team of veterinary and technical specialists, Envol has developed advanced capabilities spanning neuroscience, CNS drug delivery, cardiovascular research, musculoskeletal applications, and complex sample collection procedures. These services are performed within Envol’s facilities, allowing sponsors to work with a single integrated partner rather than coordinating multiple vendors throughout a development program.
This integrated approach improves study consistency while reducing logistical complexity and timelines.
Expanding the Possibilities of Neuroscience Research
Among Envol’s most differentiated capabilities are its advanced neurosurgical platforms.
As CNS-targeted therapeutics continue to grow in importance across gene therapy, neurodegenerative disease, and rare disease research, sponsors increasingly require specialized models that can accurately evaluate delivery, distribution, and efficacy within the brain and spinal cord.
Envol’s surgical team has established sophisticated approaches for intrathecal dosing, intracerebral administration, catheter placement, cerebrospinal fluid collection, and MRI-guided delivery procedures. These capabilities enable sponsors to investigate therapeutic candidates using administration methods that closely mirror clinical practice.
The result is higher-quality translational data and greater confidence as programs move toward regulatory submission and clinical evaluation.
More Than Surgery: A Fully Integrated Research Environment
Advanced procedures generate the greatest value when they are supported by the right scientific infrastructure.
Because Envol combines surgical expertise with imaging, pharmacology, toxicology, pathology, bioanalytical support, and core laboratory services, sponsors benefit from a seamless flow of information throughout the study lifecycle.
Samples can move directly from procedure suites into laboratory workflows. Imaging data can be correlated with pharmacokinetic and pharmacodynamic findings. Surgical observations can be incorporated into broader study endpoints without introducing additional vendors or handoffs.
This level of integration helps accelerate timelines while improving overall study quality.
Building the Scientific Leadership Needed for GLP Growth
As Envol continues expanding its capabilities, the organization has also made significant investments in the expertise required to support increasingly complex regulated studies.
A major milestone in that effort was the addition of Dr. Daniela Schwotzer as Director of Toxicology. A board-certified toxicologist with experience leading more than 120 preclinical studies, Dr. Schwotzer brings extensive expertise in GLP toxicology, study design, regulatory compliance, inhalation toxicology, CNS programs, and large-animal research. Her arrival represents another important step in Envol’s ongoing expansion of GLP support services and scientific oversight.
Combined with the organization’s continued investments in quality systems, regulatory expertise, veterinary medicine, and translational science leadership, Envol is building the infrastructure sponsors increasingly expect from modern preclinical partners.
The Future of Preclinical Research Requires Specialized Expertise
As therapies become more targeted and delivery methods more sophisticated, the importance of advanced surgical capabilities will continue to grow.
Sponsors need research partners capable of executing complex procedures, generating clinically relevant data, and supporting programs through increasingly rigorous regulatory expectations.
By combining advanced surgical services, deep NHP expertise, integrated scientific support, and a growing foundation of GLP leadership, Envol Biomedical continues to position itself as a trusted partner for organizations developing the next generation of therapeutics.
For sponsors seeking a CRO capable of delivering both technical excellence and translational insight, Envol’s expanding surgical and scientific capabilities provide a powerful advantage.